Oil prices are soaring, knocking down transportation stocks today. UPS (UPS 4.68%) shares dropped 4.9% as of 12:05 p.m. ET, potentially giving investors an opportunity. This comes just days after one Wall Street firm raised its price target on UPS, citing its valuable, capital-intensive infrastructure. The HALO effect Last week, Jefferies highlighted UPS as a key HALO trade. That term, reportedly ...
Oil prices are soaring, knocking down transportation stocks today. UPS (UPS 4.68%) shares dropped 4.9% as of 12:05 p.m. ET, potentially giving investors an opportunity. This comes just days after one Wall Street firm raised its price target on UPS, citing its valuable, capital-intensive infrastructure. The HALO effect Last week, Jefferies highlighted UPS as a key HALO trade. That term, reportedly coined by financial advisor Josh Brown, stands for "heavy asset, low obsolescence." It's meant to represent the market rotation out of sectors disrupted by artificial intelligence (AI), including software makers. Jefferies also raised its price target from $130 to $135 per share, according to reports. The new price target would represent 38% upside for UPS stock. Yet the significant tangible assets, physical infrastructure, and lasting economic importance of companies like UPS are now in focus for another reason. The sharp surge in oil prices resulting from the war with Iran is hitting transportation stocks hard today. Expand NYSE : UPS United Parcel Service Today's Change ( -4.68 %) $ -4.79 Current Price $ 97.57 Key Data Points Market Cap $87B Day's Range $ 97.01 - $ 100.63 52wk Range $ 82.00 - $ 123.70 Volume 202K Avg Vol 6.2M Gross Margin 18.53 % Dividend Yield 6.41 % Oil spiked well above $100 per barrel this morning. It has since pared some of those gains, but plenty of uncertainty remains about oil production and the effects of the Middle East conflict. Investors are considering just how high oil prices can go. Long-term investors, though, might view today's drop in UPS stock as an opportunity. Oil prices rise and fall, and the latest shock should be temporary. UPS predicts revenue will return to growth in 2026 after declining nearly 3% in 2025. Today's 5% drop could soon be a distant memory if investors jump back into the stocks of industrial companies like UPS.
The space economy has evolved past the exploratory phase and is becoming more critical to infrastructure here on Earth. With advancements in satellite technology, launch vehicles, and defense capabilities, the global space economy continues to grow rapidly. According to Novaspace's Space Economy Report, the global space economy reached $626 billion in 2025 and is projected to grow at a 12% compoun...
The space economy has evolved past the exploratory phase and is becoming more critical to infrastructure here on Earth. With advancements in satellite technology, launch vehicles, and defense capabilities, the global space economy continues to grow rapidly. According to Novaspace's Space Economy Report, the global space economy reached $626 billion in 2025 and is projected to grow at a 12% compound annual rate, reaching $1 trillion by 2034. For investors looking to capitalize on this boom in the space economy, here are three space stocks to buy in March. Rocket Lab is growing into a key end-to-end player in the space economy Rocket Lab (RKLB 2.15%) is the second-most-used space launch company in the United States. It completed 21 launches in 2025, including a record seven launches in the fourth quarter alone. Right now, Rocket Lab caters to companies looking to send small payloads into orbit with its small-lift launch vehicle, Electron. The company is seeing its revenue per launch go up. Last year, it earned $8.5 million per launch, up from $7.8 million per launch the year before. Rocket Lab plans to debut its medium-lift launch vehicle, Neutron, sometime later this year. This larger launch vehicle will enable Rocket Lab to carry payloads up to 40 times its current capacity, which should help it earn more per launch and achieve higher margins. The company was hoping to launch this in the first quarter of this year, but a setback during a hydrostatic pressure trial in January has pushed its projected launch date back to the fourth quarter. Expand NASDAQ : RKLB Rocket Lab Today's Change ( -2.15 %) $ -1.51 Current Price $ 68.60 Key Data Points Market Cap $40B Day's Range $ 67.82 - $ 71.76 52wk Range $ 14.71 - $ 99.58 Volume 8.4M Avg Vol 24M Gross Margin 31.66 % In addition to launch services, the company has a strong space systems business, designing and manufacturing components to support customers' missions. Last year, the space systems segment generated nearly $403 ...
Shares of gold miner Newmont Mining (NEM 2.82%) rallied 15.7% in February, according to data from S&P Global Market Intelligence. Newmont is the largest mining company in the world that primarily mines gold, while it also generates ancillary revenue from byproducts copper, zinc, silver, lead, and other metals. But as Newmont is primarily a gold producer, the stock is heavily levered to gold prices...
Shares of gold miner Newmont Mining (NEM 2.82%) rallied 15.7% in February, according to data from S&P Global Market Intelligence. Newmont is the largest mining company in the world that primarily mines gold, while it also generates ancillary revenue from byproducts copper, zinc, silver, lead, and other metals. But as Newmont is primarily a gold producer, the stock is heavily levered to gold prices. Gold prices rose during February, bolstering shares, while Newmont also delivered fourth-quarter earnings above consensus. Moreover, a dispute with its JV partner on a certain project actually helped bolster investor sentiment on top of all that. Expand NYSE : NEM Newmont Today's Change ( -2.82 %) $ -3.28 Current Price $ 113.01 Key Data Points Market Cap $127B Day's Range $ 109.31 - $ 113.90 52wk Range $ 42.03 - $ 134.88 Volume 260K Avg Vol 9.8M Gross Margin 49.78 % Dividend Yield 0.87 % Newmont delivers, and reins in Barrick At the beginning of the month, Newmont made an announcement regarding its joint venture with Barrick Mining (B 1.39%) that boosted shares. On February 5, Barrick announced that it intended to spin off its North American mining assets into a separate company and sell a portion of that new company in an IPO. Newmont co-owns one of the mines within the new company, holding a 38.5% stake in Barrick's Nevada Gold Mine (NGM). Following the announcement, Newmont issued a press release stating that any transaction affecting the JV must respect the protections for Newmont contained in those provisions. Newmont in particular wants Barrick to improve operations at NGM, which has seen a "degradation in performance and subsequent asset value over the past six years." It appears Newmont believes an IPO may not attract as high of a price as it otherwise would if the NGM were performing better, and it seems that Newmont wants Barrick to improve operations at that mine before the transaction. Newmont went on to deliver fourth-quarter earnings later in the month, with...
Gigantic US Error Or All Part Of A Plan? Via Rabobank, Anybody thinking US payrolls, even at -92K, matters much in the current environment is probably at the head of the queue to be replaced by an AI soon. That data series is always volatile and 2.5m undocumented workers are estimated to have left the US since Trump was re-elected: 394K foreign-born workers lost their jobs in the reported month wh...
Gigantic US Error Or All Part Of A Plan? Via Rabobank, Anybody thinking US payrolls, even at -92K, matters much in the current environment is probably at the head of the queue to be replaced by an AI soon. That data series is always volatile and 2.5m undocumented workers are estimated to have left the US since Trump was re-elected: 394K foreign-born workers lost their jobs in the reported month while the native-born series rose 877K, albeit after a shocking 2.5m drop of its own the month before. How can anyone take these numbers seriously even if the underlying signal is deadly serious? This is eclipsed by Brent oil this morning trading over $110 with WTI at $107: both look to be going exponential, perhaps even opening up the $150 scenario the GCC warn of. Worse, that doesn’t account for more dramatic moves in diesel, jet fuel, fertilizer, key chemicals like sulphur, and gases like helium, without which not a lot moves in the industrial economy, grows in the agricultural economy, or is produced in terms of metals like copper and tech goods like chips. In short, this is now starting to look like a potential combination of the 1973 post-Yom Kippur War oil shock, the 2022 Russia-Ukraine War commodity shock, and the 2020-21 Covid supply chain shock. The longer this goes on, the more exponential the damage becomes in a domino effect, which is exactly what oil is now showing to a market that saw some takes last week that ‘things could be a lot worse.’ Well, now they are: and if we are still in the same position this time next week, things could be quite terrifying. Yet while credible estimates today are that if all fighting were to suddenly cease, it would take two weeks to start to right the ship and a further two months to get back to normal, what we should call Gulf War 3 is showing many signs of widening its geography and escalating within it. On geography: even if Trump is reportedly now against using the Kurds as a military wedge against Tehran (perhaps due to Turki...
Sign up now! Sign up now! Sign up now? Sign up now! Sunderland fans have suffered enough to know that no matter how well things might appear to be going, calamity is never too far away. Take, for example, a thirtysomething mackem of Football Daily’s acquaintance who travelled to see Régis Le Bris’s side get dumped out of the FA Cup by Port Vale . Having watched his side lose 1-0 to the worst team ...
Sign up now! Sign up now! Sign up now? Sign up now! Sunderland fans have suffered enough to know that no matter how well things might appear to be going, calamity is never too far away. Take, for example, a thirtysomething mackem of Football Daily’s acquaintance who travelled to see Régis Le Bris’s side get dumped out of the FA Cup by Port Vale . Having watched his side lose 1-0 to the worst team in League One – and the one we are still following through the tournament – he cheerfully noted that the result “isn’t even in the top 10 most embarrassing things to happen to Sunderland in my lifetime”. With his team safe from relegation, Le Bris treated Port Vale with maximum respect by picking his strongest side but they still lost to a team that clearly “wanted it more”. Down here I was looking forward, courtesy of the FA Cup, to a brief break from getting up in the middle of the night to suffer through another disappointing Spurs game. So I sat down in front of the telly on a nice Sunday afternoon to cheer on fellow Aussie Oscar Piastri in the Australian Grand Prix, hoping for a win. Yep … crashed out on the formation lap. There is a pattern here and I am wondering if I have some special curse or power. If you have a particular team or sportsperson that you don’t like and want me to cheer for, my rates are reasonable” – Greg Wynn. Could we send Sergio Ramos as head coach to Cruzeiro in Brazil. Their playing philosophy appears a perfect fit (see below)“ – Krishna Moorthy. Continue reading...
Leisa Gwenllian is a force of nature as working-class heroine Effi in this big screen version of Gary Owen’s one-woman play The visceral one-woman play Iphigenia in Splott by Welsh dramatist Gary Owen has overwhelmed audiences and critics since it premiered in 2015 , reimagining the sacrificial heroine Iphigenia from Greek tragedy as a young working-class woman in Cardiff who likes a drink and a l...
Leisa Gwenllian is a force of nature as working-class heroine Effi in this big screen version of Gary Owen’s one-woman play The visceral one-woman play Iphigenia in Splott by Welsh dramatist Gary Owen has overwhelmed audiences and critics since it premiered in 2015 , reimagining the sacrificial heroine Iphigenia from Greek tragedy as a young working-class woman in Cardiff who likes a drink and a laugh, defiant in the face of pity, condescension and curtain-twitching. Now it has been recreated as a blistering Welsh-language movie by director Marc Evans, who has co-written the screenplay with Owen, with a live-wire performance from Leisa Gwenllian as Effi, a child of austerity and the Covid lockdown, reclaiming her rights to immediate pleasure and happiness in the face of long-term deprivation. At times it plays a little broad with the occasional touch of Holby City; and on a factual point, if Effi’s solicitor wanted to dissuade her from abandoning her lucrative negligence case against a hospital, he would emphasise that her payout would come from the hospital’s insurance (though, yes, the resulting increased premiums would punish future patients). Still, Effi o Blaenau is part of a British social realist tradition that extends from Ken Loach’s Poor Cow to Clio Barnard’s The Arbor, and it turns on that kitchen-sink staple no longer often found in modern drama and movies: the unplanned pregnancy. It also has what social realism often doesn’t have: an absorbing, propulsive story that keeps you on the edge of your seat. And it’s a film that doesn’t flinch from the burden of tragedy. Continue reading...
is transportation editor with 10+ years of experience who covers EVs, public transportation, and aviation. His work has appeared in The New York Daily News and City & State. Posts from this author will be added to your daily email digest and your homepage feed. When Donut Lab first announced its solid-state battery earlier this year, there was some speculation around whether the Finnish startup ha...
is transportation editor with 10+ years of experience who covers EVs, public transportation, and aviation. His work has appeared in The New York Daily News and City & State. Posts from this author will be added to your daily email digest and your homepage feed. When Donut Lab first announced its solid-state battery earlier this year, there was some speculation around whether the Finnish startup had actually produced a supercapacitor, which is a much shorter-term form of electrical storage. Supercapacitors can charge and discharge quickly, similar to Donut Lab’s claimed solid-state battery. But supercapacitors are totally different from batteries in terms of energy storage capacity and long-term use. Was Donut Lab’s battery actually just a supercapacitor in disguise? The startup says no, and it has the independent test results to prove it. The test, which was yet again conducted by state-owned VTT Technical Research Centre of Finland, “evaluates its charge retention over an extended idle period.” This is the third test in a series of independent examinations ordered by Donut Lab to evaluate its claims about its new battery. “Many have said that the specifications of Donut battery can only be achieved with supercapacitor,” the company’s CEO Marko Lehtimäki said in a video. “Well, today we are proving that is not the case.” Basically, VTT hooked up Donut Lab’s to a battery tester and left it idle for 10 days, while measuring the voltage every 10 seconds. According to the results, the cell demonstrated high stability, retaining 97.7 percent of its energy during the 10-day idle period. There was some minor fluctuation detected, with VTT reporting a drop in voltage from an initial 3861 mili-volts to 3722mV (a change of -128mV) within the first hour due to chemical stabilization. But otherwise, the cell kept the majority of its energy, which Donut Lab says disproves the theories that its battery is actually a supercapacitor. Over a similar idle period, supercapacitors will...
(AMZN) Equity Market Report Trading Plans (Long Term) No Long plans offered at this time. Short near 24.73, target n/a, stop loss @ 24.85 Check the time stamp on this data. Updated AI-Generated Signals for Amazon.com CDR (CAD Hedged) (AMZN:CA) available here. AMZN:CA Ratings for March 9: Term Near Mid Long Rating Neutral Neutral Strong â Triggers may have already come Get Real Time Triggers Here.
(AMZN) Equity Market Report Trading Plans (Long Term) No Long plans offered at this time. Short near 24.73, target n/a, stop loss @ 24.85 Check the time stamp on this data. Updated AI-Generated Signals for Amazon.com CDR (CAD Hedged) (AMZN:CA) available here. AMZN:CA Ratings for March 9: Term Near Mid Long Rating Neutral Neutral Strong â Triggers may have already come Get Real Time Triggers Here.
Taking a multivitamin every day for two years appears to slow some markers of biological ageing – albeit to a small degree – research suggests. While chronological age is based on how long a person has lived, biological age reflects the state of the body. Estimates of the latter are often based on changes in patterns of DNA methylation – modifications to DNA that accumulate with age and affect how...
Taking a multivitamin every day for two years appears to slow some markers of biological ageing – albeit to a small degree – research suggests. While chronological age is based on how long a person has lived, biological age reflects the state of the body. Estimates of the latter are often based on changes in patterns of DNA methylation – modifications to DNA that accumulate with age and affect how genes function. One theory is that by slowing the rate of biological ageing, it may be possible to prevent or mitigate age-related illness, meaning people have more years of good health. Now a study, which was carried out by researchers in the US and included funding from the confectionery manufacturer Mars, suggests a daily multivitamin could help slow some markers of biological ageing – although what that means in terms of health currently remains unclear. “Ultimately, it is critical to determine the clinical relevance of our findings,” the authors wrote. Dr Howard Sesso, a epidemiologist at Mass General Brigham department of medicine and senior author of the new work, said the findings did not mean all older adults must take multivitamins. “There are no known risks for taking a multivitamin in our two large clinical trials. At the same time, we do not know for sure who benefits, and how,” he said. While a large study published last year found daily multivitamins did not help people to live any longer and might actually increase the risk of an early death, Sesso and colleagues said their previous work had suggested daily multivitamins were associated with improved cognition, and reductions in lung cancer and cataracts. Writing in the journal Nature Medicine, Sasso and colleagues reported how 958 healthy participants with an average age of about 70 years were split into four groups. These were assigned to take either a daily cocoa extract and multivitamin; daily cocoa extract and multivitamin placebo; daily cocoa extract placebo and multivitamin; or two placebos daily. Th...
As any “Star Trek” fan will tell you, the reason why this sci fi world has endured for so long is because it illustrates an optimistic future, with tech starring as a power for good. In fact, famed XPrize founder, author, tech investor, motivational speaker and longevity guru Peter Diamandis has just launched a new $3.5 million Future Vision Xprize to encourage more such optimistic sci-fi worlds t...
As any “Star Trek” fan will tell you, the reason why this sci fi world has endured for so long is because it illustrates an optimistic future, with tech starring as a power for good. In fact, famed XPrize founder, author, tech investor, motivational speaker and longevity guru Peter Diamandis has just launched a new $3.5 million Future Vision Xprize to encourage more such optimistic sci-fi worlds to come to our screens. He credits his whole fabulous career to watching “Star Trek” as a child growing up. “’Star Trek’ offered a hopeful vision of the future, right? It was humans/humanity and technology in collaboration,” Diamandis told TechCrunch. “I truly credit it with everything that I since achieved, because it motivated me to want to go and create and manifest that future.” He finds that sci-fi movies and TV shows these days are largely fixated on calamity. “Every science fiction movie I was seeing painted this dystopian vision of the future. It was always, everything is going wrong, and it’s a result of technology. You know, killer robots, dystopian AIs. It’s ‘Black Mirror’. It’s ‘Terminator’. It’s ‘Ex Machina,’” he said. “Why would you ever want to live in that future?” So he called up his friends Rod Roddenberry, son of “Star Trek” creator Gene Roddenberry, billionaire Salesforce CEO Marc Benioff, famed investor and CEO of Ark Cathie Wood, and his buddies at Google. They all agreed to sponsor the new XPrize Future Vision. Techcrunch event Disrupt 2026: The tech ecosystem, all in one room Your next round. Your next hire. Your next breakout opportunity. Find it at TechCrunch Disrupt 2026, where 10,000+ founders, investors, and tech leaders gather for three days of 250+ tactical sessions, powerful introductions, and market-defining innovation. Register now to save up to $400. Save up to $300 or 30% to TechCrunch Founder Summit 1,000+ founders and investors come together at TechCrunch Founder Summit 2026 for a full day focused on growth, execution, and real-world sca...
News that a business is slashing prices isn't great if you're worried about its margins and overall profitability. But offering reduced prices can, however, help with winning market share. As a result, it's not always obvious whether a move to reduce prices can be beneficial for a stock in the long run. Pharmaceutical giant Novo Nordisk (NVO +2.96%) is planning to drastically reduce the list price...
News that a business is slashing prices isn't great if you're worried about its margins and overall profitability. But offering reduced prices can, however, help with winning market share. As a result, it's not always obvious whether a move to reduce prices can be beneficial for a stock in the long run. Pharmaceutical giant Novo Nordisk (NVO +2.96%) is planning to drastically reduce the list prices of its popular GLP-1 treatments, including Ozempic and Wegovy, next year. The company has been facing growing competition, and investors may be concerned that this is confirmation of its struggles in the hotly competitive weight loss market. However, here's why I think that this can prove to be a great move for Novo Nordisk in the long run, and why investors may benefit from it. Up to a 50% cut coming next year Starting in 2027, Novo Nordisk plans to make its popular GLP-1 drugs far more attractively priced. At $675 per month, the list price for its GLP-1 medications will be up to 50% lower for patients; Wegovy, which is approved for weight loss, currently has a list price of $1,349. For people who have high deductibles, this can make the treatments far more accessible. The company, however, is likely going to offset some of the price decline by reducing rebates. This comes as there is increased pressure from the government to lower drug prices. And it could intensify the competition with key rival Eli Lilly, whose weight loss drug Zepbound has been helping people achieve greater weight loss than Wegovy. At around $1,100 per month, Zepbound's list price is currently a bit lower than Wegovy's. Expand NYSE : NVO Novo Nordisk Today's Change ( 2.96 %) $ 1.14 Current Price $ 39.72 Key Data Points Market Cap $130B Day's Range $ 38.50 - $ 39.76 52wk Range $ 35.85 - $ 82.57 Volume 725K Avg Vol 24M Gross Margin 80.90 % Dividend Yield 4.48 % Why this could help Novo Nordisk's stock By offering a lower price for Wegovy and other GLP-1 drugs, Novo Nordisk may be in a better position ...
To say that cannabis producer Canopy Growth (CGC 1.40%) has been an underwhelming buy in recent years would be a massive understatement. The Canadian-based cannabis company has been in an endless free fall. Five years ago, the company's market cap was around $14 billion. Today, however, it's worth less than $500 million. For investors who have bought the dip on Canopy Growth amid its tailspin, the...
To say that cannabis producer Canopy Growth (CGC 1.40%) has been an underwhelming buy in recent years would be a massive understatement. The Canadian-based cannabis company has been in an endless free fall. Five years ago, the company's market cap was around $14 billion. Today, however, it's worth less than $500 million. For investors who have bought the dip on Canopy Growth amid its tailspin, they've been rewarded with significant losses. And it begs the question of whether there is any viable reason to invest in this once-promising growth stock today? Why can't Canopy Growth stock catch a break? The big reason to invest in Canopy Growth several years ago was due to the hope that marijuana legalization would soon take place in the U.S. and that the company would be able to capitalize on some tremendous growth opportunities. As a leading cannabis producer in Canada, it was often seen as the top cannabis stock to own. Unfortunately, hopes for legalization simply haven't panned out, and the U.S. is arguably no closer to legalizing marijuana now than it was five years ago. In the meantime, the cannabis producer hasn't been able to do much to impress investors. The company has incurred losses totaling 326.6 million Canadian dollars over the trailing 12 months, and during that time frame, it has also burned through CA$78.7 million just from its day-to-day operating activities. And in its most recent quarter, which ended on Dec. 31, 2025, the company's net revenue was flat at CA$74.5 million. The company is still struggling to generate much growth in a highly competitive Canadian cannabis market, where margins are thin. And its efforts to become leaner and more efficient have failed to get the business anywhere near profitability, leaving little wonder as to why investors have generally steered clear of the stock. Expand NASDAQ : CGC Canopy Growth Today's Change ( -1.40 %) $ -0.01 Current Price $ 1.05 Key Data Points Market Cap $362M Day's Range $ 1.03 - $ 1.06 52wk Range...
This year is inevitably going to be a different one from previous ones for Berkshire Hathaway (BRKA 1.22%)(BRKB 1.15%) as Warren Buffett is no longer at the helm. While new CEO Greg Abel, who took over at the start of the year, is maintaining the culture and keeping things largely as they were under Buffett, there likely will be some changes along the way. And while the business may still be in st...
This year is inevitably going to be a different one from previous ones for Berkshire Hathaway (BRKA 1.22%)(BRKB 1.15%) as Warren Buffett is no longer at the helm. While new CEO Greg Abel, who took over at the start of the year, is maintaining the culture and keeping things largely as they were under Buffett, there likely will be some changes along the way. And while the business may still be in strong financial shape, it may have lost a bit of its luster. It's been a sluggish start to the year for Berkshire, whose stock is down around 2% thus far. To make matters worse, the company also reported some underwhelming quarterly numbers recently. Is the stock destined to decline further this year, or can it be a good buy right now? Berkshire's earnings fell last quarter, but investors are likely focused on the new CEO For the last three months of 2025, Berkshire's operating earnings totaled $10.2 billion, which were down around 30% from the $14.5 billion the company reported in the same period last year. The big drop was mainly due to its insurance business. However, when looking at the full year, the decline was not nearly as dramatic, with Berkshire's operating earnings totaling $44.5 billion versus $47.4 billion a year ago -- equating to a much more modest decline of 6%. The underwhelming earnings numbers did lead to a slight decline in Berkshire's share price. However, the stock has remained fairly stable; over the past six months, its performance has been flat. The bigger concerns are arguably to do with what happens with the company and its investments under the new leadership. However, in Abel's first letter to shareholders, the new CEO emphasized that the company will deploy the same approach and strategy to its investments as it did under Buffett. "We will assess value carefully, act patiently, and hold for the long term." Expand NYSE : BRKB Berkshire Hathaway Today's Change ( -1.15 %) $ -5.76 Current Price $ 493.22 Key Data Points Market Cap $1.1T Day's Range $...